Schema therapy meanwhile is widely used, especially for personality disorders and in outpatient treatment. Still there is a need for a more profound evidence based research. In this symposium, we present the results of some recently published (or submitted) RCTs. Eva Fassbinder (Kiel) will present recent data of the PRO*BPD-Study comparing the efficacy of the so far best-evaluated treatments for Borderline Personality disorder, i.e. Dialectical Behavior Therapy (DBT) and Schema therapy (ST). Arnoud Arntz (Amsterdam) will give insights into the large multi-center RCT with almost 500 participants from 5 countries comparing solely group ST with combined group- and individual treatment and Treatment-as-usual (TAU). David Bernstein (Maastricht) will report on a RCT in Dutch forensic hospitals comparing ST and TAU. Finally, Marit Kool (NPI/Arkin) compares dosage effects (25 vs. 50 sessions) in an RCT with a psychodynamic and a ST setting with major depressive disordered clients with comorbid personality disorder(s). In sum, the presentations will give an up to date overview on the most important international developments in ST and will be of major interest for both psychotherapists and researchers.
17:15 Uhr
The PRO*BPD-study: comparing dialectical behavior therapy (DBT) and schema therapy (ST) for borderline personality disorder
E. Fassbinder (Lübeck, DE)
17:37 Uhr
Group schema therapy with borderline personality disorder: results of an international randomized controlled trail
E. Fassbinder (Kiel, DE)
18:01 Uhr
Efficacy of schema therapy in a forensic setting
D. Bernstein (Maastricht, NL)
Details anzeigen
Autor:in:
D. Bernstein (Maastricht, NL)
In this presentation, Prof. Bernstein will discuss innovative methods, based on Schema Therapy, for treating patients with severe personality disorders and aggression to push the boundaries of treatability. The talk will highlight both individual therapy and milieu-therapy ('SafePath') approaches
18:23 Uhr
Dose effects of schema therapy in patients with major depressive disorder and comorbid personality disorders
M. Kool (Amsterdam, NL)
Details anzeigen
Autor:in:
M. Kool (Amsterdam, NL)
Introduction: Higher psychotherapy dosages may improve depression treatment outcome, especially in cases were a personality disorder (PD) complicates treatment.
Objective: We examined whether higher dosages of integrated psychotherapy (addressing both depression and PD) improved outcome in depression, by comparing 25 individual sessions (starting weekly) with 50 sessions (starting twice weekly) in one year.
Methods: In this pragmatic, double-randomized clinical trial, 246 adult outpatients with depression/dysthymia and PD were randomly assigned to 25 or 50 sessions of either Short-term Psychoanalytic Supportive Psychotherapy (SPSP) or Schema Therapy (ST), stratified by depression severity. The primary outcomes were depression severity (BDI-II) over time in the intention-to-treat sample and remission of depression (MINI) at end of treatment.
Results: Psychotherapy dosage had a significant effect on depression severity (BDI-II) over time in favor of 50 sessions. After 50 sessions more patients no longer met the criteria for depression/dysthymia than after 25 sessions and 50 sessions also resulted in better personality outcomes. No difference was found between ST and SPSP.
Conclusions: A higher psychotherapy dosage should be considered for this group as it had a stronger effect on both depression and personality and could therefore reduce recurrence, treatment levels and costs. Long-term studies of effectiveness and cost-effectiveness are needed, in addition to research looking at working mechanisms.